Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?
AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer
AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
Immune-Mediated Adverse Events With Concomitant Radiotherapy and Immunotherapy
Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer
EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma
AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC
Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer
HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer
Pembrolizumab Approved by FDA for Cutaneous Squamous Cell Carcinoma
ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC
ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases
EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma
ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC
First-in-Class Immunotherapy With Azacitidine Under Study in AML
ASCO20: Can Radioiodine Plus Durvalumab Improve Outcomes in Resistant Thyroid Cancer?
ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC
ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL
EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma
Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma
ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?
ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
ASCO20: Longer-Term Follow-Up Supports Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer
ASCO20: Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer
ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer
EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL
ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer
ASCO20: Treating Anaplastic Thyroid Cancer Based on Driver Mutations
ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma
ASCO20: Combination Immunotherapy for Aggressive Thyroid Cancers
ASCO20: Selinexor-Based Combination Therapy for Resistant Multiple Myeloma
Can Viral Immunotherapy Reverse Platinum Resistance in Ovarian Cancer?
ASCO20: Adding T-DM1 to Targeted Therapy for High-Risk Early Breast Cancer
ASCO20: ‘Modest Antitumor Activity’ for Pembrolizumab in Recurrent Ovarian Cancer
ASCO20: Lenvatinib Plus Pembrolizumab in Radioiodine-Refractory Thyroid Cancer
Chemotherapy-Free Treatment of CLL: Acalabrutinib With or Without Obinutuzumab
ASCO20 Preview: Should Pembrolizumab Replace Chemotherapy in First-Line Treatment of Some Colorectal Cancers?
Novel Antibody-Drug Conjugate Under Study in Resistant Multiple Myeloma
FDA Approves Chemotherapy Plus Immunotherapy Combination in First-Line Treatment of Resistant NSCLC
Use of Live Attenuated Vaccines in Teenagers Treated With Imatinib for CML
Combination Therapy of Paclitaxel, Carboplatin, and Pembrolizumab in Ovarian Cancer
Biologic Therapies for Patient With Both Multiple Myeloma and Lung Cancer
FDA Approves Atezolizumab for Metastatic NSCLC With High PD-L1 Expression
Ofatumumab Treatment and Rare Viral Infection of the Brain : A Case Study in CLL
COVID-19 and Multiple Myeloma: 60-Year-Old Man Successfully Treated With Tocilizumab


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.